Regeneron And Bluebird Team Up In Cell Therapy "Joint Venture"-Style Deal
Regeneron will make a $100m equity investment in bluebird to collaborate on the discovery of antibodies and T cell receptors, with the hope of building out in immuno-oncology and overcoming some of the early cell therapy challenges. Regeneron's business development chief talks to Scrip about its strategy.
You may also be interested in...
Senior VP-global clinical development David Weinreich addresses the company's growing investment in oncology drug development, why Regeneron is well positioned to lead in the area, and business development.
In an exclusive interview, one of the most direct CEOs in the industry, Regeneron’s Len Schleifer, clarifies his attitude to drug pricing and growing internal innovation.
Bluebird has been an active deal maker as it looks to add tools, targets and technological capabilities to its R&D engine. A pair of August TCR-focused deals, including the latest with Gritstone, continue that strategy.